CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 100 enrolled
Drug / intervention
Progesterone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06812559
NCT06812559N/ACompleted
CompareCT.gov

Progesterone Primed Ovarian Stimulation Versus Gonadotrophin-Releasing Hormone Antagonist in Women With Polycystic Ovarian Syndrome

El Shatby University Hospital for Obstetrics and Gynecology·observational·Posted Feb 6, 2025·Updated Feb 25, 2025

In Brief

An observational study evaluating Progesterone and GnRH antagonist (Cetrorelix) for Controlled Ovarian Hyperstimulation and Polycystic Ovarian Syndrome. Completed, enrolled 100 participants across 1 site.

Detailed Summary

The purpose of this study is to compare the use of the progesterone-primed ovarian stimulation protocol versus GnRH antagonist protocol in women with polycystic ovarian syndrome (PCOS) regarding the number of oocytes retrieved, percentage of MII oocytes, and the rate of good quality blastocysts available for cryopreservation.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsControlled Ovarian Hyperstimulation, Polycystic Ovarian Syndrome
CountriesEgypt
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedFeb 6, 2025
Enrollment StartDec 1, 2023
Primary CompletionFeb 1, 2025
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 1.4 years ago

Interventions

Progesteronedrug

compare the use of the progesterone-primed ovarian stimulation protocol versus GnRH antagonist protocol in women with polycystic ovarian syndrome (PCOS) regarding the number of oocytes retrieved, percentage of MII oocytes, and the rate of good quality blastocysts available for cryopreservation.

GnRH antagonist (Cetrorelix)drug

Subcutaneous injection